Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2024

The benign prostatic hyperplasia (bph) treatment devices and equipment market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth witnessed in the past period can be attributed to several factors, including an aging population, increased awareness and diagnoses, expanded healthcare access, and the development of personalized treatment approaches.

The benign prostatic hyperplasia (bph) treatment devices and equipment market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. Anticipated growth in the upcoming period can be attributed to several factors such as the adoption of minimally invasive techniques, expanding markets in emerging economies, support from regulatory bodies, and the advancement of value-based healthcare models. Major trends expected during this period include the prominence of non-surgical and office-based procedures, the utilization of laser and radiofrequency technologies, the increased implementation of telemedicine and remote consultations, and a growing emphasis on patient education and engagement.

Benign Prostatic Hyperplasia (BPH), also known as Prostate Gland Enlargement (PGE), is characterized by uncomfortable urinary symptoms in patients. The increasing prevalence of BPH has led to a growing demand for BPH treatment devices and equipment. As the number of reported BPH cases continues to increase, the demand for these devices is expected to rise correspondingly. For instance, in 2021, over 14 million men in the United States exhibited symptoms of BPH, and globally, around 30 million men experienced BPH-related symptoms. This rise in BPH cases is anticipated to drive the demand for BPH treatment devices and equipment.

The primary offerings in the market for devices and equipment aimed at treating Benign Prostatic Hyperplasia (BPH) include resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants. Resectoscopes serve as endoscopic tools employed in surgeries involving the uterus, prostate, bladder, or urethra, enabling the extraction of tissue for biopsy, removal of growths, or ablation of diseased or damaged tissue. Various procedures conducted encompass transurethral needle ablation (TUNA), transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), laser surgery, among others. The diverse user segments involved in utilizing these products include hospitals, ambulatory surgical centers (ASCs), clinics, and home-based applications.

The benign prostatic hyperplasia (BPH) treatment market research report is one of a series of new reports that provides benign prostatic hyperplasia (BPH) treatment market statistics, including benign prostatic hyperplasia (BPH) treatment industry global market size, regional shares, competitors with a benign prostatic hyperplasia (BPH) treatment market share, detailed benign prostatic hyperplasia (BPH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia (BPH) treatment industry. This benign prostatic hyperplasia (BPH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticipated rise in prostate cancer cases is set to fuel the expansion of the benign prostatic hyperplasia (BPH) market. With prostate cancer impacting a growing number of men, there is an increased need for medical attention among older males regarding prostate-related issues. This surge in cancer cases contributes to the identification and management of benign prostatic hyperplasia. According to the American Society of Clinical Oncology (ASCO), estimations in 2023 suggested about 288,300 men were affected by prostate cancer in the United States. The year 2022 witnessed 268,490 new cases and 34,500 deaths related to prostate cancer. This trajectory in prostate cancer cases is a significant driver behind the growth of the benign prostatic hyperplasia market.

The market for BPH devices and equipment encounters a significant restraint due to patient-experienced side effects following BPH procedures. For instance, common side effects of such surgeries include urinary incontinence, urination discomfort, and challenges in fully emptying the bladder. These experiences deter patients suffering from BPH from opting for surgical procedures (unless absolutely necessary), leading to reduced demand for such treatments. Consequently, this decreased demand affects the utilization of devices by key end-users such as hospitals, clinics, and ambulatory surgical centers.

Prostatic Artery Embolization (PAE) represents a cutting-edge advancement in the field of Benign Prostatic Hyperplasia (BPH) treatment devices and equipment. It offers a minimally invasive approach to alleviating urinary tract symptoms related to BPH. PAE employs state-of-the-art imaging technologies, including X-rays, to visualize and treat the tumor inside the body without the need for invasive surgery. This technique significantly reduces treatment complications associated with BPH. Notable industry leaders such as Boston Scientific, UNC Healthcare, and Spire Healthcare have made substantial investments in the development and advancement of PAE technologies, emphasizing the growing significance of this innovation in the BPH treatment market.

Major companies in the benign prostatic hyperplasia market are heavily invested in creating innovative solutions, such as the UroLift 2 System and UroLift ATC advanced tissue control system, aimed at delivering dependable services to the market. Specifically designed to address lower urinary tract symptoms related to benign prostatic hyperplasia (BPH), these systems are developed to offer enhanced treatment methodologies. For example, in May 2022, Teleflex Incorporated, a US-based medical device company, introduced the UroLift 2 System and UroLift ATC. The UroLift 2 System is a specialized delivery system crafted to access the prostatic urethra and implant permanent UroLift devices through the prostate's lobes. On the other hand, the UroLift ATC advanced tissue control system is a minimally invasive procedure created to manage symptoms stemming from an enlarged prostate. These innovations represent an evolutionary approach in treating benign prostatic hyperplasia (BPH), addressing the obstruction of the urethra by lifting and holding the enlarged prostate tissue.

In March 2021, Olympus Corporation, a Japan-based producer of optical and reprographic tools, completed the acquisition of Medi-Tate, strengthening its urology division and broadening its range of minimally invasive treatment offerings. The acquisition was strategically aimed at bolstering the company's portfolio of non-surgical solutions, enhancing men's healthcare, and improving overall quality of life. Medi-Tate, an Israel-based medical device firm, is focused on delivering effective, non-surgical treatments to elevate men's health and wellness.

Major companies operating in the benign prostatic hyperplasia (BPH) treatment devices and equipment market include Karl Storz, Lumenis Ltd., Olympus Corporation, Urologix LLC, Boston scientific Inc., Endo International PLC, NeoTract Inc., OmniGuide Inc., Medifocus Inc., ProArc Medical Ltd., Teleflex Incorporated, Medtronic PLC, Urotech Devices, Prostalund Operations AB, Baxter International, NxThera Inc., Richard Wolf GmbH, Coloplast A/S, Siemens Healthineers, Quest Pharmatech, Protox Therapeutics, IntelGenx Technologies Corp, Astellas Pharma Inc., Ipsen S.A., Biolitec AG, BVM Medical, Convergent Laser Technologies, Cook Medical, GreenLight Technologies, Merit Medical Systems, Pnn Medical A/S, PROCEPT BioRobotics, Prosenex, ProSolv CardioVascular Inc., Quanta System, Rocamed SAM, RZ Medizintechnik GmbH, SRS Medical Systems, UroShape LLC, Vertebron Inc.

North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2023. Western Europe was the second-largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in the benign prostatic hyperplasia (BNH) treatment devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the benign prostatic hyperplasia (BPH) treatment devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The benign prostatic hyperplasia (BPH) treatment devices and equipment market consist of sales of prostatic stents, catheter ablation devices, resectoscopes, radiofrequency ablation devices, urology lasers, and prostatic stents that are used to treat benign prostatic hyperplasia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.